Collaborative data hub for improving liquid biopsy cancer detection
Official title: Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit
Funded at Fred Hutchinson Cancer Center · NIH-11406125 · Data updated 2026-11-12
A nationwide collaboration will manage data and coordinate studies to improve how blood tests can detect cancer early.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $792,000 |
| NIH project number | 5U24CA288185-04 |
| Project ID | NIH-11406125 on NIH RePORTER |
Who could benefit from this research
✓Could help
People at risk for cancer or undergoing screening who may benefit from earlier detection through blood-based tests.
✕Less likely to help
Individuals without access to participating centers or who are not part of the testing populations may not directly benefit.
What this research studies
This grant supports a data management and coordinating unit within a liquid biopsy consortium, aiming to standardize data, enhance study design, and streamline multi-site research. By organizing complex biomarker data from blood and other fluids, it helps researchers develop more reliable early cancer tests. The project emphasizes robust statistics, data sharing, and coordinating across centers to overcome validation challenges in diverse populations.
Why it matters
Potential benefit: If successful, this work could lead to more accurate and earlier cancer detection through liquid biopsy, potentially reducing cancer spread and deaths.
How similar studies have gone: Previous liquid biopsy efforts show promise, but success depends on robust data coordination and validation across populations.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Zheng, Yingye — Fred Hutchinson Cancer Center
- Study coordinator: Zheng, Yingye
Related research
Other NIH-funded projects on the same topics.
-
Towards a blood-based test using nanophotonic exosomes to screen and diagnose liver cancer
A new blood test using tiny particles shed by liver cancer cells aims to screen for hepatocellular carcinoma earlier and more accurately.
-
Liquid biopsy test to screen for lymphoma in people with HIV
A new blood test called High Density Methyl-Seq is being checked to see if it can detect lymphoma early in people living with HIV.
-
Liquid biopsy and oxygen therapy to guide glioblastoma treatment
A patient-focused study exploring a blood-based test and a safe oxygen therapy to help doctors tell true tumor growth from treatment effects in adults with glioblastoma treated with chemoradiation.
-
Liquid biopsy to monitor LMS treatment and resistance
A patient-centered look at using blood tests to see how well LMS treatment is working and when resistance to therapy appears.
-
Imagnostix: a simple blood-based test to flag Alzheimer’s risk
A new blood-based test called Imagnostix aims to help identify people who may be developing Alzheimer’s disease earlier and more cheaply than current methods.
-
Multi-omic liquid biopsy to guide immunotherapy in colorectal and anal cancers
A patient-facing overview of a study testing blood-based biomarkers (ctDNA and extracellular RNA) to better tailor immunotherapy for colorectal and anal cancer patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.